14-day Premium Trial Subscription Try For FreeTry Free
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA

12:20pm, Tuesday, 14'th Feb 2023 Zacks Investment Research
With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2

Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You Should Know

10:50pm, Monday, 13'th Feb 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.54, moving +0.45% from the previous trading session.

Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why

05:45pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth

5 Best High Earnings Yield Picks to Grow Your Wealth

12:45pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Stocks with high earnings yield have the potential to provide greater returns. PTEN, JBL, CPRX, AGCO and URBN are some stocks boasting high earnings yield to power your portfolio.
Stocks with high earnings yield have the potential to provide greater returns. PTEN, JBL, CPRX, AGCO and URBN are some stocks boasting high earnings yield to power your portfolio.
Catalyst Pharmaceutical (CPRX) closed at $15.87 in the latest trading session, marking a -1.43% move from the prior day.
The search for growth stocks, or companies with high potential for future growth, is on. These growth stocks often represent young, rapidly-expanding companies that are reinvesting their earnings bac
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Catalyst's rights acquisition of FYCOMPA is a significant step towards controlling the epilepsy treatment market share. The company's cash balance of $256 million is enough to fund its CapEx in 2023.
Style Box ETF report for JPSE
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE